Ironwood Pharmaceuticals, Inc. - Class A
IRWDIronwood Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for gastrointestinal and other specialty health conditions. Known for its expertise in microbiome and gastrointestinal biology, Ironwood's portfolio includes products and pipelines aimed at improving patient outcomes through innovative treatments.
Company News
U.S. stock futures rose on Monday as major indices opened the first full trading week of 2026 higher. Following the U.S. strike on Venezuela and removal of President Maduro, crude oil prices fluctuated around $57.29 per barrel. Several stocks gained attention: Vertiv Holdings jumped on an upgrade, GH Research soared on FDA update news, Nukkleus r...
Ironwood Pharmaceuticals shares surged 36% on January 2, 2026, after announcing 2026 financial guidance that significantly exceeded Wall Street expectations. The company expects LINZESS U.S. net sales of $1.125-1.175 billion (vs. $860-890M in 2025) and total revenue of $450-475 million (vs. consensus of $319.5M), driven by a strategic list price ...
Ironwood Pharmaceuticals' stock plunged after the FDA requested a confirmatory Phase 3 trial for its gastrointestinal drug apraglutide, despite strong data from the initial trial.
Beam Therapeutics, a biotechnology company developing precision genetic medicines, has appointed Sravan K. Emany as its new Chief Financial Officer. Emany brings extensive experience in the life sciences industry and will help guide Beam's growth and capital allocation strategy.
Three stocks were added to the Zacks Rank #5 (Strong Sell) list today: Arcos Dorados Holdings Inc., Ironwood Pharmaceuticals, Inc., and Avnet, Inc. The Zacks Consensus Estimate for their current year earnings has been revised downward over the last 60 days.
